Medivation, Inc. (MDVN)

81.44
NASDAQ
Prev Close 81.44
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Medivation Inc Stock Upgraded (MDVN)

Medivation Inc Stock Upgraded (MDVN)

Medivation (Nasdaq:MDVN) has been upgraded by TheStreet Ratings from a sell to hold.

Ratings Changes Today

Upgrades: ARCP, DATE, FDP, KELYB, MDVN, MERC, NGL, RCII, SPH, WRE Downgrades: ANF, BID, EPIQ, HE, PLPM, POWR, RMTI, STS, TPC, TRLA Initiations: CMRX, ENTA, EVTC, GFN, TMHC, WBB Read on to get TheStreet Quant Ratings' detailed report:

Medivation (MDVN) Is Today's Dead Cat Bounce Stock

Medivation (MDVN) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Medivation (MDVN) as a "dead cat bounce" (down big yesterday but up big today) candidate

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Medivation (MDVN) as a post-market leader candidate

A View on Ariad Pharma's Bloated Valuation

A View on Ariad Pharma's Bloated Valuation

Even at $86 million in 2014 Iclusig sales, Ariad trades at a lofty and unjustified 13 times enterprise value. For comparison's sake, Medivation's EV/sales multiple is 9 -- and that's only counting U.S. sales of its growing prostate cancer drug Xtandi.

Commit To Buy Medivation At $45, Earn 12.8% Using Options

Commit To Buy Medivation At $45, Earn 12.8% Using Options

Investors eyeing a purchase of Medivation Inc stock, but tentative about paying the going market price of $59.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2016 put at the $45 strike, which has a bid at the time of this writing of $5.75.

Medivation (MDVN) Marked As A Dead Cat Bounce Stock

Medivation (MDVN) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Medivation (MDVN) as a "dead cat bounce" (down big yesterday but up big today) candidate

Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis

Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis

Exelixis shares fall after independent data monitors concluded a closely watched phase III study of cabozantinib in advanced prostate cancer should continue to the final analysis expected later this year.

Why Medivation (MDVN) Is Down Today

Why Medivation (MDVN) Is Down Today

Medivation (MDVN) falls after the biopharmaceutical company forecasts guidance that came up well short of analysts' expectations.

Heavy Volume And Pre-Market Movement For Medivation (MDVN)

Heavy Volume And Pre-Market Movement For Medivation (MDVN)

Trade-Ideas LLC identified Medivation (MDVN) as a pre-market mover with heavy volume candidate

Today's Post-Market Laggard: Medivation (MDVN)

Today's Post-Market Laggard: Medivation (MDVN)

Trade-Ideas LLC identified Medivation (MDVN) as a post-market laggard candidate

New Lifetime High Today: Medivation (MDVN)

New Lifetime High Today: Medivation (MDVN)

Trade-Ideas LLC identified Medivation (MDVN) as a new lifetime high candidate

'Mad Money' Lightning Round: Sell, Sell, Sell Baidu

'Mad Money' Lightning Round: Sell, Sell, Sell Baidu

Wendy's is doing everything right and Cramer isn't backing away from Sirius XM.

Jim Cramer's 'Mad Money' Recap: 10 Reasons the Market Is Falling

Jim Cramer's 'Mad Money' Recap: 10 Reasons the Market Is Falling

It doesn't matter whether the companies themselves are doing good or bad, the markets are sending everything lower, Cramer laments.

Analysts' Actions: AMAT KLAC LRCX MA MDVN

Analysts' Actions: AMAT KLAC LRCX MA MDVN

Here are today's top research calls.

Today's Perilous Reversal Stock: Medivation (MDVN)

Today's Perilous Reversal Stock: Medivation (MDVN)

Trade-Ideas LLC identified Medivation (MDVN) as a "perilous reversal" (up big yesterday but down big today) candidate

Jim Cramer's 6 Stocks in 60 Seconds: VMW MDVN WLP KORS DHI TDC (Update 1)

Jim Cramer's 6 Stocks in 60 Seconds: VMW MDVN WLP KORS DHI TDC (Update 1)

Cramer says everyone loves VMware but Michael Kors is a volatile stock.

Medivation Inc. (MDVN): Today's Featured Drugs Winner

Medivation Inc. (MDVN): Today's Featured Drugs Winner

Medivation was a winner within the drugs industry, rising $8.51 (11.2%) to $84.29 on heavy volume

4 Health Care Stocks On The Rise

4 Health Care Stocks On The Rise

TheStreet highlights 4 stocks pushing the health care sector higher today.

Medivation's Xtandi Curves Are Kate Upton-esque: An Update

Medivation's Xtandi Curves Are Kate Upton-esque: An Update

With these new Xtandi data, Medivation and Astellas have what they need to overtake J&J in the pre-chemo prostate cancer treatment market.

Medivation (MDVN): Heavy Pre-Market Activity

Medivation (MDVN): Heavy Pre-Market Activity

Trade-Ideas LLC identified Medivation (MDVN) as a pre-market mover with heavy volume candidate

Medivation: First Look At Xtandi Pre-Chemo Prostate Cancer Survival Curves

Medivation: First Look At Xtandi Pre-Chemo Prostate Cancer Survival Curves

Xtandi reduced the risk of death by 29% compared to placebo in the phase III "PREVAIL" study.

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Medivation (MDVN) as a post-market leader candidate

First Week Of September 20th Options Trading For Medivation (MDVN)

First Week Of September 20th Options Trading For Medivation (MDVN)

Investors in Medivation Inc saw new options begin trading this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

New Lifetime High Reached By Medivation (MDVN)

New Lifetime High Reached By Medivation (MDVN)

Trade-Ideas LLC identified Medivation (MDVN) as a new lifetime high candidate

'Fast Money' Recap: Negative Pre-Announcements

'Fast Money' Recap: Negative Pre-Announcements

The trading panel discussed whether investors should worry that 94 companies on the S&P, a seven-year high, expect lower earnings.

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas: Medivation (MDVN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Medivation (MDVN) as a post-market leader candidate

J.P. Morgan Healthcare Confab Live Blog: Day One

J.P. Morgan Healthcare Confab Live Blog: Day One

TheStreet's Adam Feuerstein is providing live coverage all week from the biotech sector's most important investor conference.

Analysts Issue Bullish Biotech Outlooks for '14, Except Goldman, Which Is Negative

Analysts Issue Bullish Biotech Outlooks for '14, Except Goldman, Which Is Negative

The favorite stocks of the sell-side for 2014 include Gilead Sciences, Vertex, NPS Pharma, Medivation and Regeneron Pharma.

Big Pharma Stocks: Year in Review

Big Pharma Stocks: Year in Review

Expect drug stocks to make new highs in 2014. But be selective.